1. Pink Sheet

Restasis IPR Reprieve: Federal Circuit Stays PTAB Action Until June

 
• By Brenda Sandburg

Appeals court to address whether Mohawk Tribe has sovereign immunity before inter partes review proceeding goes forward; Federal Circuit may leave it to Congress to decide question.

Court of Appeals for Federal Circuit Lafayette Park Across from White House Washington DC

The Saint Regis Mohawk Tribe and Allergan Inc. won a stay of inter partes review (IPR) of Restasis (cyclosporine) patents until the US Court of Appeals for the Federal Circuit decides whether the Tribe has sovereign immunity that shields it from the proceedings. However, the delay does not reflect on the ultimate outcome of the dispute and the validity of the patents.

The Mohawk Tribe appealed a February decision by the US Patent and Trademark Office's Patent Trial and Appeal Board (PTAB)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited

 
• By Derrick Gingery

The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-force was finalized.

US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines

 
• By Sarah Karlin-Smith

US FDA's cancer drugs division is feeling the effect of drug reviewer departures, despite efforts to keep them at the agency.

Australia Targets Clinical Trial Reform, AI Use And Drug Shortages In 12-Month Plan

 
• By Eliza Slawther

Reforming clinical trial regulations, addressing the use of artificial intelligence, mitigating medicines shortages and strengthening ties with other drug regulators are key priorities for Australia’s Therapeutic Goods Administration over the next year.